In the first half of 2025, Sothema took a major step forward in Morocco’s pharmaceutical landscape by introducing the country’s first generic treatment for multiple sclerosis made with glatiramer acetate. This locally manufactured drug fills a long-standing gap in the Moroccan healthcare system, which until now lacked any approved therapy—brand-name or generic—based on this molecule.
This breakthrough was one of eleven new products launched by the company during the first six months of the year, with seven developed and produced entirely within Morocco. It’s part of a broader push by Sothema to strengthen its presence in critical therapeutic areas like allergy care, ophthalmology, and gastroenterology—fields that represent urgent public health priorities.
The rollout of this multiple sclerosis treatment reflects more than just a product launch—it underscores Sothema’s commitment to delivering accessible, innovative healthcare solutions designed and made in Morocco. For patients living with a complex neurological disease that previously had no domestic treatment options, this marks a significant leap forward.
This strategic move toward therapeutic innovation aligns with the company’s wider plan to diversify its product portfolio and bolster its industrial capacity. That direction was further confirmed during its mid-year earnings report, where Sothema announced a 17% increase in consolidated revenue, reaching 1.549 billion dirhams.
